{"data":[{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Levy Guy","reportingCik":null,"personType":"IN","sharesOwned":3378378,"percentOfClass":5.2,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus Capital Management, L.P.","reportingCik":null,"personType":"PN","sharesOwned":3378378,"percentOfClass":5.2,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus GP, LLC","reportingCik":null,"personType":"OO","sharesOwned":3378378,"percentOfClass":5.2,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus Capital, LLC","reportingCik":null,"personType":"OO","sharesOwned":2702702,"percentOfClass":4.2,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus Capital Master Fund, L.P.","reportingCik":null,"personType":"FI","sharesOwned":2702702,"percentOfClass":4.2,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus Capital Group, LLC","reportingCik":null,"personType":"OO","sharesOwned":2702702,"percentOfClass":4.2,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus Private Equity GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":675676,"percentOfClass":1,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus Private Equity Fund III, L.P.","reportingCik":null,"personType":"PN","sharesOwned":675676,"percentOfClass":1,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001213900-26-076456","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2026-04-21","reportingPerson":"Soleus PE GP III, LLC","reportingCik":null,"personType":"OO","sharesOwned":675676,"percentOfClass":1,"filedAt":"2026-07-08","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001346824-26-000121","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Incorporated","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-21","reportingPerson":"Rajeev Shah","reportingCik":null,"personType":"HC,IN","sharesOwned":6477309,"percentOfClass":9.9,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001346824-26-000121","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Incorporated","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-21","reportingPerson":"RA Capital Management, L.P.","reportingCik":null,"personType":"IA,PN","sharesOwned":6477309,"percentOfClass":9.9,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001346824-26-000121","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Incorporated","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-21","reportingPerson":"Peter Kolchinsky","reportingCik":null,"personType":"HC,IN","sharesOwned":6477309,"percentOfClass":9.9,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001346824-26-000121","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Incorporated","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-21","reportingPerson":"RA Capital Healthcare Fund, L.P.","reportingCik":null,"personType":"PN","sharesOwned":6477309,"percentOfClass":9.9,"filedAt":"2026-04-28","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0000947871-26-000463","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"COMMON STOCK","eventDate":"2026-04-21","reportingPerson":"ORBIMED ADVISORS LLC","reportingCik":"0001055951","personType":"IA","sharesOwned":12935071,"percentOfClass":16,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0000947871-26-000463","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"COMMON STOCK","eventDate":"2026-04-21","reportingPerson":"ORBIMED CAPITAL GP VI LLC","reportingCik":"0001682115","personType":"OO","sharesOwned":11808945,"percentOfClass":14.6,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0000947871-26-000463","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"COMMON STOCK","eventDate":"2026-04-21","reportingPerson":"OrbiMed Genesis GP LLC","reportingCik":"0001808744","personType":"OO","sharesOwned":1126126,"percentOfClass":1.4,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0000947871-26-000463","formType":"SCHEDULE 13D/A","amendmentNo":3,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"COMMON STOCK","eventDate":"2026-04-21","reportingPerson":"ORBIMED CAPITAL LLC","reportingCik":"0001157524","personType":"IA","sharesOwned":789500,"percentOfClass":1,"filedAt":"2026-04-23","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001104659-26-046848","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-20","reportingPerson":"Baker Bros. Advisors LP","reportingCik":"0001263508","personType":"IA,PN","sharesOwned":10295301,"percentOfClass":15.5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001104659-26-046848","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-20","reportingPerson":"Baker Bros. Advisors (GP) LLC","reportingCik":"0001580575","personType":"HC,OO","sharesOwned":10295301,"percentOfClass":15.5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001104659-26-046848","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-20","reportingPerson":"Julian C. Baker","reportingCik":"0001087939","personType":"IN,HC","sharesOwned":10295301,"percentOfClass":15.5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001104659-26-046848","formType":"SCHEDULE 13D/A","amendmentNo":5,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":"74065P101","securityClass":"Common Stock, $0.0001 par value per share","eventDate":"2026-04-20","reportingPerson":"Felix J. Baker","reportingCik":"0001087940","personType":"IN,HC","sharesOwned":10295301,"percentOfClass":15.5,"filedAt":"2026-04-22","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0000929638-26-000626","formType":"SCHEDULE 13G/A","amendmentNo":6,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics Inc","ticker":"PRLD","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-12-31","reportingPerson":"Vaddi Krishna","reportingCik":null,"personType":"IN","sharesOwned":6745647,"percentOfClass":13.15,"filedAt":"2026-02-13","canonicalUrl":"https://xoomar.com/markets/stocks/prld"},{"accessionNo":"0001104659-25-108459","formType":"SCHEDULE 13G","amendmentNo":null,"issuerCik":"0001678660","issuerName":"Prelude Therapeutics, Inc.","ticker":"PRLD","cusip":null,"securityClass":"Common Stock, par value $0.0001 per share","eventDate":"2025-11-03","reportingPerson":"INCYTE CORP","reportingCik":null,"personType":"CO","sharesOwned":4372124,"percentOfClass":9.9,"filedAt":"2025-11-07","canonicalUrl":"https://xoomar.com/markets/stocks/prld"}],"updatedAt":"2026-11-04T07:57:41.860Z","source":"xoomar.com","docs":"https://xoomar.com/markets/api","license":"https://xoomar.com/terms","attribution":"Credit XOOMAR with a link to the dataset page on xoomar.com when you republish this data","canonicalUrl":"https://xoomar.com/markets/stocks/prld","meta":{"source":"SEC","sourceAttribution":"Schedule 13D and 13G data: SEC.","notice":"10 requests a minute without a key, 30 with a free key. Get a free key at https://xoomar.com/signup?utm_source=api, register your app at https://xoomar.com/developers/register?utm_source=api, and credit the data as \"Data: XOOMAR\" together with the sourceAttribution line."}}